The fact that (1) anti-resorptive therapy with bisphosphonates is already known to eradicate DTCs in the BM [18] and that (2) circulating levels of serum RANKL are elevated in DTC-positive breast cancer patients [33], provided a strong rationale for us to hypothesize that anti-resorptive denosumab likewise promotes the eradication of DTCs in the BM. Here, TNFSF11 is linked to breast carcinoma.